



Infectious Diseases Working Party

Chair:	Rafael de la Camara	Secretary:	Dina Averbuch
Statistician:	Gloria Tridello	Nurse:	Marta Canesi
Study Coordinator Lead:	Nina Knelange	Study Coordinator:	Lotus Wendel
Data Manager:	Inge Verheggen	Data Entry Clerk:	Juana Schwartz Mota

IDWP in the past year

Major Achievements

2022 was a special year for the IDWP!

Firstly, it was the 30th anniversary of its creation in 1992 with Prof. Per Ljungman as its first chair. Moreover, after two years marked by the SARS-CoV-2 pandemic, we gradually came back to normal. Although the pandemic continues, the impact and lethality has decreased globally, also for our HCT patients. Consequently, the generous funding from EBMT for SARS-CoV-2 activities was finalized at the end of 2022. Also, we were finally able to have a face-to-face meeting again with a splendid 25th IDWP EBMT Educational Course in Florence, Italy.



25th IDWP EBMT Educational Course (3-5 November, Florence, Italy)

In 2022-2023, we had 16 publications, of which 8 were focused on Covid-19, 16 lectures, 4 oral presentations and 7 poster communications at international congresses. In June, we actively participated in the 11th Annual Conference of the SSBMT/EBMT 2022 in Riyadh, Saudi Arabia. In September, we were involved in the 9th European Conference on Infections in Leukemia (ECIL) in Nice, France, and in the 22nd Symposium of the International Immunocompromised Host Society (ICHS) in Basel, Switzerland, where we had a joint session with the American Society for Transplantation and Cellular Therapy (ASTCT) and Prof. Per Ljungman received the ICHS Lifetime Achievement award!

Principal Research Studies

- Impact of Covid-19 on stem cell transplant recipients and CAR-T cell recipients
P. Ljungman
- Central nervous system disorders following HSCT: A prospective observational study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP)
M. Schmidt-Hieber
- Non-tuberculous mycobacterial infections post-HSCT
M. Stamouli
- Incidence and outcome of Adenovirus infections in haploidentical HSCT
M. Faraci
- Children with SARS-CoV-2 infection following HCT
D. Averbuch
- Real-world outcomes of letermovir use in primary prophylaxis in adult cytomegalovirus seropositive allogeneic HCT recipients: A multicenter retrospective cohort IDWP study from the EBMT Registry
J. Styczynski

Key Publications in 2022

1. Mycobacterial infections in adults with hematological malignancies and hematopoietic stem cell transplants: Guidelines from the 8th European Conference on Infections in Leukemia
1st listed author: Anne Bergeron. Journal: Lancet Infect Dis (IF 71.421)
2. Recommendations for the management of COVID-19 in patients with hematological malignancies or hematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukemia (ECIL 9)
1st listed author: Simone Cesaro. Journal: Leukemia (IF 12.883)
3. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A survey of the Infectious Diseases Working Party of EBMT
1st listed author: Simone Cesaro. Journal: Bone Marrow Transplant (IF 5.483)
4. Discrepancies in the management of *Clostridioides difficile* infections in patients after allogeneic hematopoietic cell transplantation: The results of the Infectious Diseases Working Party EBMT survey
1st listed author: Agnieszka Piekarska, Journal: Bone Marrow Transplant (IF 5.483)
5. Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of the Infectious Diseases Working Party EBMT
1st listed author: Jan Styczynski, Journal: Transpl Infect Dis. (IF 2.228)

Contact IDWP:
idwp.ebmt@lumc.nl

49th Annual Meeting of EBMT (23-26 April, Paris, France)

IDWP Business Meeting: Monday, April 24, 7:00-8:45h

IDWP Working Party Session: Monday, April 24, 9:00-10:15h

1. *D. Averbuch* – What is new in the management of neutropenic fever?
2. *G. Papanicolaou* – An old foe and new friends: Hot topics in management of CMV
3. *C. Cordonnier* – How to prevent and treat toxoplasmosis in HSCT patients – New ECIL recommendations
4. *M. Mikulska* – Top 10 papers in HSCT infections (2022-2023)

Oral presentations

- *O. Penack* – Influence of pre-existing invasive aspergillosis on allo-HSCT outcome in acute leukemia patients: A prospective study of the EBMT Infectious Diseases Working Party (OS08-01)
- *J. Styczynski* – Frequencies, management and new treatment modalities of EBV-DNA-EMIA and EBV-PTLD after allo-HCT: Survey of IDWP-EBMT (OS08-07)
- *J. Styczynski* – Real-world outcomes of letermovir use in primary prophylaxis in adult cytomegalovirus seropositive allogeneic HCT recipients: A multicenter retrospective cohort IDWP study from the EBMT Registry (OS09-01)
- *M. Griffin* – Observational study of 361 non-transplanted aplastic anemia and/or PNH patients who received Covid-19 vaccination: Joint report from the Severe Aplastic Anemia & Infectious Diseases EBMT Working Parties (OS12-06)
- *R. Greco* – Outcome of SARS-CoV-2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases (OS13-03)

Other infection-related sessions

- **IS07 Industry Symposium: Updates in CMV in HSCT: State of the Art | MSD**, April 23, 10:30-12:00
- **IS23 Industry Symposium: Moving Forward: What's New for CMV Management | TAKEDA**, April 23, 16:30-18:00h
- **E04 Educational: Vaccination after allogeneic transplantation**, April 24, 14:30-16:00h



- **GS02 Presidential Symposium**, April 24, 16:30-18:00h
P. Ljungman – Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with Covid-19: An IDWP study from the EBMT Registry
(Left: Prof. Per Ljungman receiving the ICHS Lifetime Achievement award from Prof. Hans Hirsch)

- **MTE-07 Meet the Expert Session**, April 25, 8:00-9:00h
P. Ljungman – How I prevent and treat CMV infection
- **NG11 Nurses Group: Infections**, April 25, 9:00-10:30h
- **IS32 Industry Symposium: Optimizing antifungal treatment options in patients with neutropenic haematological disease | GILEAD**, April 25, 13:00-14:00h
- **MTE-13 Meet the Expert Session**, April 26, 8:00-9:00h
D. Averbuch – How to treat the resistant gram-negative bacteria in HCT patients
- **OS08 Oral Session 8: Infectious complications (I)**, April 26, 10:30-11:45h
- **OS09 Oral Session 9: Infectious complications (II)**, April 26, 10:30-11:45h
- **SS06-6 GOCART ongoing projects**, April 26, 12:30-13:45h
D. Averbuch – Infections following CAR-T therapy | A retrospective collaborative study between the IDWP, CTIWP, TCWP of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin

Poster presentations

- *J. De Greef* – Risk factors and prognosis of *Nocardia* infection after allogeneic hematopoietic stem cell transplantation: An Infectious Diseases Working Party and Franco-Belgian *Nocardia* study group case-control study (P391)
- *M. Mikulska* – Predictors of length of SARS-CoV-2 positivity in hospital-admitted HSCT recipients with Covid-19: An Infectious Disease Working Party study (P392)

Planned for 2023

- Fusarium infections in HSCT recipients (*D. Averbuch*)
- Outcome of non-cryopreserved auto-HSCT (*E. Snarski*)
- HIV infections after HSCT (*A. Paviglianiti*)
- Infections following CAR-T therapy (*D. Averbuch*, chosen as GOCART project)

Educational activities

26th IDWP EBMT Educational Course (16-18 November, Athens, Greece)

www.ebmt.org